- DehydraTECH™ is patent protected for multiple Active Pharmaceutical Ingredients (APIs) including hemp oil CBD and cannabis, nicotine, non-steroidal anti-inflammatory drugs, and fat-soluble vitamins
- Lexaria has 16 patents granted and over 60 patent applications pending worldwide
- DehydraTECH™ shown to facilitate rapid uptake and highly targeted delivery of pharmaceuticals to the brain
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, is accelerating its patented DehydraTECH based drug delivery technology and formulation development. Funding received from the first tranche of Lexaria’s previously announced private placement of units, issued at a price of $0.45 per unit, realized gross proceeds of $699,410, which will be used to advance several company-wide goals (http://cnw.fm/vJ8up).
Earlier this year, Lexaria moved into its new head office that includes a Health Canada licensed research and development laboratory that is being used to conduct world-leading research into drug delivery methods and improvements. In addition to accelerating research in the company’s DehydraTECH drug delivery platform, Lexaria is also considering issuing a limited commercial release of DehydraTECH version 2.0, which has been shown to deliver 811% more CBD into animal blood than generic industry control formulations, the company stated in an update to shareholders (http://cnw.fm/VV6qg).
Lexaria’s focus on pioneering new technologies that can more efficiently deliver APIs into the bloodstream, where they can have their desired effect, includes developing an effective way to cross the blood-brain-barrier. Lexaria’s DehydraTECH version 2.0 is showing promise in this arena as testing indicated 1,937% more CBD reached animal brain tissue compared to generic industry control formulations.
Cannabidiol is emerging as a promising compound to treat or prevent movement disorders, such as those seen in Parkinson’s disease patients, according to an article published by the National Institutes of Health (http://cnw.fm/uI7lD). Extending the range of drugs available for therapeutic use to treat neurological conditions such as Alzheimer’s and Parkinson’s disease is a critical area of study since there currently is no effective treatment for these diseases, according to an article in Physics World (http://cnw.fm/2IlQ6).
Lexaria’s dedication to research and development can be seen in its strong and growing intellectual property portfolio. As of August 2019, the company’s patent portfolio includes approximately 60 patent applications filed and pending in more than 40 countries around the world, with 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX
About CanadianCannabisWire
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.canadiancannabiswire.com
Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
CanadianCannabisWire (CNW)
Toronto, Ontario
www.canadiancannabiswire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com
CanadianCannabisWire is part of the InvestorBrandNetwork.